EYEG - Eyegate: Speculative Buy For Their Better-Than-SOC Treatment In Corneal Wound Repair

Positive Pivotal Top-Line data

EyeGate Pharmaceuticals, Inc. (EYEG) is a clinical stage specialty pharmaceutical company that develops products for treating eye diseases and disorders.

On Nov 22, 2019, EYEG announced that their PRK (photorefractive keratectomy) study has met its primary end point:

The results of this critical study demonstrated that EyeGate’s OBG eye drop provided a greater improvement in corneal re-epithelialization than those treated with the standard-of-care, a bandage contact lens. The statistical significance measurement was based on the number of subjects in each arm that achieved complete corneal defect closure